1807988-47-1

Usage

Uses

Used in Pharmaceutical Industry:
N²-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-N⁴-(4-fluorophenyl)-6-morpholino-1,3,5-triazine-2,4-diamine is used as a kinase inhibitor for targeting the c-Met kinase, which is involved in promoting cancer cell growth and metastasis. Its inhibitory activity against this kinase makes it a potential drug candidate for the treatment of certain types of cancer.
Used in Medicinal Chemistry Research:
N²-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-N⁴-(4-fluorophenyl)-6-morpholino-1,3,5-triazine-2,4-diamine is used as a subject of ongoing research in the field of medicinal chemistry. Its potential as an anti-cancer agent and its ability to inhibit various kinases make it a valuable tool for understanding the mechanisms of cancer cell growth and developing new therapeutic strategies.
Used in Cancer Treatment Development:
N²-(4-(1H-benzo[d]imidazol-2-yl)phenyl)-N⁴-(4-fluorophenyl)-6-morpholino-1,3,5-triazine-2,4-diamine is used in the development of cancer treatments, particularly for cancers where the c-Met kinase plays a significant role in tumor progression. Its potential as a targeted therapy offers hope for more effective and personalized cancer treatments in the future.

Upstream product

• 2963-77-1 4-(1H-benzimidazol-2-yl)aniline 
• 131468-33-2 (4,6-dichloro-[1,3,5]triazin-2-yl)-(4-fluorophenyl)-amine 
• 110-91-8 morpholine 
• 371-40-4 4-fluoroaniline 
• 150-13-0 4-amino-benzoic acid 
• 95-54-5 1,2-diamino-benzene 

Relevant academic research and scientific papers

Triazine-benzimidazole conjugates: Synthesis, spectroscopic and molecular modelling studies for interaction with calf thymus DNA

Triazine-benzimidazole analogues with different substitutions of primary and secondary amines as well as aryl groups were synthesized and characterized by 1H, 13C NMR and mass spectrometry. Interactions of these compounds with ct-DNA were explored by spectroscopic and viscometric techniques. These results and molecular modelling studies showed that compounds 7, 9-11, 16 and 21 interacted with ct-DNA through groove binding and not intercalation.

Synthesis and characterization of new s-triazine bearing benzimidazole and benzothiazole derivatives as anticancer agents

Two new series of s-triazine derivatives appended with benzimidazole (15a-h) and benzothiazole derivatives (16a-h) are synthesized, and structure-activity relationships on anticancer activity of these 15a-h and 16a-h were probed. In vitro inhibitory activity against the growth of six cancer cell lines, viz., MCF-7, MDAMB-231, PC-3, DU-145, HT-29 and HGC-27 was evaluated for synthesized analogues. Among the two series of compounds, derivatives containing benzimidazole scaffold were found to be relatively potent over benzothiazole analogues. In accordance with our previous observation, within benzimidazole derivatives, tri-substituted s-triazine derivatives were found to be more potent over di-substituted derivatives irrespective of cell lines. Structure-activity relationships provided useful insights into these classes of compounds and paved the way to design novel analogues with more potency.